Brazil antimicrobial rule prompts shift at Phibro Animal Health (PAHC)
Rhea-AI Filing Summary
Phibro Animal Health Corporation describes a new Brazilian rule that will phase out growth-promotion uses of certain antimicrobial feed additives, including its virginiamycin and bacitracin products. Brazil’s Ministry of Agriculture and Livestock published Ordinance No. 1617, which bans the import, manufacture, marketing and use of these performance-enhancing additives.
The prohibition takes effect after a 180-day transition period, during which current products and labels may still be used and sold. Phibro is pursuing new registrations of virginiamycin for therapeutic use in cattle and broiler chickens and notes its bacitracin product already has therapeutic claims in Brazil. Under the new framework, future use of these antimicrobials will require a veterinary prescription, and Phibro is introducing its PhibroVet digital platform in Brazil to help manage prescriptions. The company expects this regulatory change to have limited impact on its fiscal year 2026 results and plans to provide further detail on its May 7, 2026 earnings call.
Positive
- None.
Negative
- None.
Insights
Brazil tightens antimicrobial rules; Phibro sees limited near-term impact.
Brazil is banning performance-enhancing feed additives that use antimicrobials important in human or veterinary medicine, including Phibro’s virginiamycin and bacitracin products. A 180‑day transition period allows continued sales under existing labels while the market adjusts.
Phibro is working with the Brazilian regulator on new therapeutic registrations for virginiamycin in cattle and broiler chickens, and its bacitracin already has therapeutic claims. After the transition, using these products will require veterinary prescriptions, and Phibro is rolling out its PhibroVet digital prescription platform.
The company states it expects only limited impact on fiscal 2026 results based on the transition timing. Longer-term effects will depend on how quickly therapeutic indications are approved and adopted and how Brazilian customers shift from growth-promotion uses to prescription-based therapeutic use.
8-K Event Classification
Key Figures
Key Terms
performance enhancing feed additives financial
therapeutic use financial
veterinary prescription financial
digital platform technical
forward-looking statements regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices, including Zip Code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 7.01 REGULATION FD DISCLOSURE.
On April 27, 2026, Phibro Animal Health Corporation (the “Company”), issued a press release regarding Ordinance No. 1617, published on April 27, 2026 by the Brazilian Ministry of Agriculture and Livestock (MAPA), prohibiting the importation, manufacture, marketing and use of performance enhancing feed additives containing antimicrobials classified as important in human or veterinary medicine, including Phibro’s virginiamycin and bacitracin products. This prohibition will come into effect after a transition period of 180 days from the date of the Ordinance. During such transition period, companies and customers may continue to use and sell the products under their current labels. The Company has been actively engaged with MAPA on new registrations of virginiamycin for therapeutic use in cattle and broiler chickens, which are in the final stages of review and approval by MAPA and are expected during the transition period. The Company’s bacitracin product already carries therapeutic claims in Brazil. Based on the 180 day transition period, the Company expects the regulatory change to have limited impact on its fiscal year 2026 results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Item 7.01 and in the press release is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
| Exhibit Number |
Description | |
| 99.1 | Press Release, dated April 27, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| PHIBRO ANIMAL HEALTH CORPORATION | ||
| Registrant | ||
| Date: April 27, 2026 | ||
| By: | /s/ Judith Weinstein | |
| Name: | Judith Weinstein | |
| Title: | Senior Vice President, General Counsel and Corporate Secretary | |
Exhibit 99.1
For Immediate Release
Phibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials
TEANECK, N.J., April 27, 2026 (Business Wire) — Phibro Animal Health Corporation (Nasdaq: PAHC) today announced expected implementation of a new regulatory framework governing the use of certain antimicrobials in Brazil that have growth promotion indications.
The Brazilian Ministry of Agriculture and Livestock (MAPA) published Ordinance No. 1617 on April 27, 2026, prohibiting the importation, manufacture, marketing and use of performance enhancing feed additives containing antimicrobials classified as important in human or veterinary medicine, including virginiamycin and bacitracin. This regulation brings Brazil into alignment with regulatory approaches adopted in other global markets. This prohibition will come into effect after a transition period of 180 days from the date of the Ordinance, during such times companies and customers may continue to use and sell the products under their current labels.
Phibro is working cooperatively with MAPA and relevant industry associations to support an orderly transition. The Company has been actively engaged with MAPA on new registrations of virginiamycin for therapeutic use in cattle and broiler chickens. These registrations are in the final stages of review and approval by MAPA and are expected during the transition period.
Phibro’s bacitracin product already carries therapeutic claims in Brazil.
Under the new regulatory framework, following the transition period, use of the subject antimicrobials will require a veterinary prescription. To support compliance and operational efficiency, Phibro is making available to the Brazilian market PhibroVet®, a digital platform designed to facilitate the creation, transmission, and management of veterinary prescriptions and prescription history.
Based on the 180 day transition period, the Company expects the regulatory change to have limited impact on its fiscal year 2026 results. Additional information will be provided during the Company’s upcoming earnings call scheduled for May 7, 2026.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. The Company strives to be a trusted partner to livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions that help maintain and enhance animal health. For more information, visit www.pahc.com.
1
Forward-Looking Statements
DISCLOSURE NOTICES
Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.
Internet Posting of Information: We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Contact for Phibro Animal Health Corporation
Phibro Animal Health Corporation
Glenn C. David
Chief Financial Officer
+1-201-329-7300
or
investor.relations@pahc.com
2